Protalix BioTherapeutics, Inc. (DE) revenue breakdown overview

Protalix BioTherapeutics, Inc. (DE) revenue for the last year amounted to 65.49 M USD, the most of which — 38.35 M USD — came from its highest performing source at the moment, Recombinant Therapeutic Proteins, the year earlier bringing 47.64 M USD. The greatest contribution to the revenue figure was made by Global — last year it brought Protalix BioTherapeutics, Inc. (DE) 21.60 M USD, and the year before that — 22.35 M USD.